ARL4A

Across TCGA pan-cancer cohorts, ARL4A Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ARL4A data layer compared with 21 for mass-spec protein.

The strongest signal is observed in esophageal carcinoma (ESCA), where higher ARL4A Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated ARL4A expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.

ESCA, UCEC, and BLCA are the cancer types where ARL4A Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ESCA	DFS	Median	II,III,IV	0.082	0.523	<.001	12	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
BLCA	OS	Median	III,IV	0.212	0.684	.016	3	view →
LIHC	OS	Median	II,III,IV	0.225	0.617	.044	3	view →
SKCM	DFS	Median	All	1.000	0.614	.033	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ARL4A–ESCA (DFS)

Open the ESCA breakdown →